Gastric transitional zones, areas where Helicobacter treatment fails: Results of a treatment trial using the Sydney strain mouse model

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2249-2255

  Veldhuyzen van Zanten, Sander J O ^a,d   Kolesnikow, Tassia ^b   Leung, Vincent ^c   O'Rourke, Jani L ^b   Lee, Adrian ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNITED CHRISTIAN HOSPITAL   (Hong Kong)

^d QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; METRONIDAZOLE; OMEPRAZOLE; TETRACYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH ANTRUM; TREATMENT FAILURE;

AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; METRONIDAZOLE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PENICILLINS; PYLORIC ANTRUM;

EID: 0037636486     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2249-2255.2003     Document Type: Article

References (41)

1. Akada, J. K., M. Shirai, H. Takeuchi, M. Tsuda, and T. Nakazawa. 2000. Identification of the urease operon in Helicobacter pylori and its control by mRNA decay in response to pH. Mol. Microbiol. 36:1071-1084.
2. Andersen, L. P., H. Colding, and J. E. Kristiansen. 2000. Potentiation of the action of metronidazole on Helicobacter pylori by omeprazole and bismuth subcitrate. Int. J. Antimicrob. Agents 14:231-234.
3. Ani, A. E., A. O. Malu, J. A. Onah, D. M. M. Queiroz, G. Kirschner, and G. A. Rocha. 1999. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. Trans. R. Soc. Trop. Med. Hyg. 93:659-661.
4. Asghar, R. J., and J. Parsonnet. 2001. Helicobacter pylori and risk for gastric adenocarcinoma. Semin. Gastrointest. Dis. 12:203-208.
5. Atherton, J. C., A. Cockayne, M. Balsitis, G. E. Kirk, C. J. Hawkey, and R. C. Spiller. 1995. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxycillin and cimetidine. Gut 36:670-674.
6. Bamba, H., Y. Kondo, R. M. Wong, S. Sekine, and F. Matsuzaki. 1997. Minimum inhibitory concentration of various single agents and the effect of their combinations against Helicobacter pylori, as estimated by a fast and simple in vitro assay method. Am. J. Gastroenterol. 92:659-662.
7. Bell, G. D., K. U. Powell, S. M. Burridge, A. F. Bowden, W. Atoyebi, G. H. Bolton, P. H. Jones, and C. Brown. 1995. Rapid eradication of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 9:41-46.
8. Danon, S. J., J. L. O'Rourke, N. D. Moss, and A. Lee. 1995. The importance of local acid production in the distribution of Helicobacter felis in the mouse stomach. Gastroenterology 108:1386-1395.
9. Dick-Hegedus, E., and A. Lee. 1991. Use of a mouse model to examine anti-Helicobacter pylori agents. Scand. J. Gastroenterol. 26:909-915.
10. Erah, P. O., A. F. Goddard, D. A. Barrett, P. N. Shaw, and R. C. Spiller. 1997. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice - relevance to the treatment of Helicobacter pylori infection. J. Antimicrob. Chemother. 39:5-12.
11. Evans, D. G., D. J. Evans, and D. Y. Graham. 1992. Adherence and internalisation of Helicobacter pylori by HEp-2 cells. Gastroenterology 102:1557-1567.
12. Glupczynski, Y., M. Delmee, C. Bruck, M. Labbe, V. Avesani, and A. Burette. 1988. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents. Eur. J. Epidemiol. 4:154-157.
13. Goddard, A. F., M. J. Jessa, D. A. Barrett, P. N. Shaw, J. P. Idstrom, C. Cederberg, and R. C. Spiller. 1996. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111:358-367.
14. Grayson, M. L., G. M. Eliopoulos, M. J. Ferraro, and R. C. J. Moellering. 1989. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur. J. Clin. Microbiol. Infect. Dis. 8:888-889.
15. Grove, D. I., G. Koutsouridis, and A. G. Cummins. 1998. Comparison of culture, histopathology and urease testing for the diagnosis of Helicobacter pylori gastritis and susceptibility to amoxycillin, clarithromycin, metronidazole and tetracycline. Pathology 30:183-187.
16. Hazell, S. L., T. J. Borody, A. Gal, and A. Lee. 1987. Campylobacter pyloridis gastritis I: detection of urease as a marker of bacterial colonization and gastritis. Am. J. Gastroenterol. 82:292-296.
17. Hirschl, A. M., and M. Pletschette. 1989. Antibiotic treatment of Campylobacter pylori infection, p. 217-224. In B. J. Rathbone and R. V. Heatley (ed.), Campylobacter pylori and gastroduodenal disease. Blackwell Scientific Publications Ltd., Oxford, England.
18. Hirschl, A. M., and M. L. Rotter. 1996. Amoxicillin for the treatment of Helicobacter pylori infection. J. Gastroenterol. 31(Suppl. 9):44-47.
19. Jenks, P. J., R. L. Ferrero, J. Tankovic, J. M. Thiberge, and A. Labigne. 2000. Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice. Antimicrob. Agents Chemother. 44:2623-2629.
20. Jenks, P. J., A. Labigne, and R. L. Ferrero. 1999. Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice. Antimicrob. Agents Chemother. 43:777-781.
21. Karita, M., M. K. R. Tummuru, H. P. Wirth, and M. J. Blaser. 1996. Effect of growth phase and acid shock on Helicobacter pylori caga expression. Infect. Immun. 64:4501-4507.
22. Kuipers, E. J., J. G. Kusters, and W. A. Deboer. 1997. Current therapies of Helicobacter pylori infection. Bailliere's Clin. Infect. Dis. 4:395-412.
23. Kuipers, E. J., A. M. Uyterlinde, A. S. Pena, H. Hazenberg, E. Bloemena, J. Lindeman, E. C. Klinkenbergknol, and S. Meuwissen. 1995. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am. J. Gastroenterol. 90:1401-1406.
24. Larsson, H., E. Carlsson, B. Ryberg, J. Fryklund, and B. Wallmark. 1988. Rat parietal cell function after prolonged inhibition of gastric acid secretion. Am. J. Physiol. 254:G33-G39.
25. Lee, A., M. F. Dixon, S. J. Danon, E. Kuipers, F. Megraud, H. Larsson, and B. Mellegard. 1995. Local acid production and Helicobacter pylori: a unifying hypothesis of gastroduodenal disease. Eur. J. Gastroenterol. Hepatol. 7:461-465.
26. Lee, A., J. O'Rourke, M. C. De Ungria, B. Robertson, G. Daskalopoulos, and M. F. Dixon. 1997. A standardized mouse model of Helicobacter pylori infection - introducing the Sydney strain. Gastroenterology 112:1386-1397.
27. Lind, T., F. Megraud, P. Unge, E. Bayerdorffer, C. O'Morain, R. Spiller, S. V. van Zanten, K. D. Bardhan, M. Hellblom, M. Wrangstadh, L. Zeijlon, and C. Cederberg. 1999. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 116:248-253.
28. Lind, T., S. Veldhuyzen van Zanten, P. Unge, R. Spiller, E. Bayerdorffer, C. O'Morain, K. Dev Bardhan, et al. 1996. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter 1:138-144.
29. Logan, R. P. H., M. M. Walker, J. J. Misiewicz, P. A. Gummett, Q. N. Karim, and J. H. Baron. 1995. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 36:12-16.
30. Malfertheiner, P., F. Megraud, C. O'Morain, A. P. S. Hungin, R. Jones, A. Axon, D. Y. Graham, G. Tytgat, M. Asaka, F. Bazzoli, B. Birkner, J. Bures, A. Burette, P. Bytzer, L. Castro, A. Culhane, W. de Boer, J. De Korwin, E. De Koster, N. de Wit, M. Deltenre, J. Dent, F. Di Mario, B. Dragosics, M. Farkkila, et al. 2002. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 consensus report. Aliment. Pharmacol. Ther. 16:167-180.
31. Marshall, B. J., and J. R. Warren. 1984. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet i:1311-1315.
32. McGowan, C. C., A. Necheva, S. A. Thompson, T. L. Cover, and M. J. Blaser. 1998. Acid-induced expression of an LPS-associated gene in Helicobacter pylori. Mol. Microbiol. 30:19-31.
33. Megraud, F. 1995. Rationale for the choice of antibiotics for the eradication of Helicobacter pylori. Eur. J. Gastroenterol. Hepatol. 7(Suppl. 1):S49-S54.
34. Mirshahi, F., G. Fowler, A. Patel, and G. Shaw. 1998. Omeprazole may exert both a bacteriostatic and a bacteriocidal effect on the growth of Helicobacter pylori (NCTC 11637) in vitro by inhibiting bacterial urease activity. J. Clin. Pathol. 51:220-224.
35. Peterson, W. L., D. Y. Graham, B. Marshall, M. J. Blaser, R. M. Genta, P. D. Klein, C. W. Stratton, J. Drnec, P. Prokocimer, and N. Siepman. 1993. Clarithromycin as monotherapy for eradication of Helicobacter pylori - a randomized, double-blind trial. Am. J. Gastroenterol. 88:1860-1864.
36. Treiber, G. 1996. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am. J. Gastroenterol. 91:246-257.
37. Unge, P. 1997. What other regimens are under investigation to treat Helicobacter pylori infection. Gastroenterology 113(Suppl. 6S):S131-S148.
38. Veldhuyzen van Zanten, S. J. O., M. F. Dixon, and A. Lee. 1999. The gastric transitional zones: neglected links between gastroduodenal pathology and Helicobacter ecology. Gastroenterology 116:1217-1229.
39. Veldhuyzen van Zanten, S. J. V., P. T., Pollak, H. Kapoor, and P. K. Yeung. 1996. Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori. Dig. Dis. Sci. 41:1845-1852.
40. Velduyzen van Zanten, S. J. O., and P. M. Sherman. 1994. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can. Med. Assoc. J. 150:177-185.
41. Xia, H. X., N. J. Talley, C. T. Keane, and C. A. O'Morain. 1997. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig. Dis. Sci. 42:1821-1834.